What a talar dome lesion actually is

Your scan report says 'talar dome lesion' — and if that phrase means little to you, you are not alone. Here is what it actually describes.

The talus is the bone that sits at the top of the ankle joint, forming the rounded dome that bears the full weight of your body every time you take a step. Its upper surface is lined with articular cartilage — a smooth, shock-absorbing layer a few millimetres thick. Directly beneath that cartilage sits a denser layer called subchondral bone, which gives the cartilage its structural foundation.

A talar dome lesion — the clinical term is osteochondral lesion of the talus, or OLT — means that both layers have been damaged together. The cartilage has cracked, softened, or partially detached, and the bone underneath has also been affected. This dual injury is what makes it distinct from a surface scuff: without an intact bony bed, the cartilage cannot repair itself reliably.

Importantly, this is not a condition that develops gradually with age. OLT is disproportionately common in younger, active adults aged 20 to 40, and the cause is almost always trauma. Up to 50% of significant ankle sprains and over 70% of ankle fractures are associated with osteochondral damage to the talus — often going unnoticed at the time because the symptoms closely resemble a straightforward sprain.

Why a talar dome lesion is so often mistaken for a sprain

The difficulty is in the overlap. Deep ankle pain, intermittent swelling, and a sense of the joint being unreliable after a twist or fall are all consistent with a standard lateral ligament sprain — and in the vast majority of cases, that is exactly what they are. A talar dome lesion produces the same picture, at least in the early weeks.

What separates the two is time and pattern. A sprain that responds to rehabilitation and settles within six to eight weeks is behaving as expected. One that lingers — particularly with swelling that returns after activity, or a persistent ache deep within the joint rather than along the outer ligaments — is signalling that something more than soft tissue is involved. At that point, repeating the same conservative management without imaging is unlikely to move things forward.

Mechanical symptoms are the clearest escalation trigger. Catching, clicking, or a sensation of the ankle momentarily locking during movement suggests that a fragment of cartilage or bone is loose or unstable within the joint. This is not a feature of a ligament sprain and warrants prompt specialist assessment rather than further waiting.

The clinical cost of a prolonged delay is real. Articular cartilage does not self-repair readily, and an unstable osteochondral fragment left unaddressed can enlarge and accelerate wear of the joint surface — raising the risk of post-traumatic ankle osteoarthritis in a group of patients who are, on average, still in their thirties.

How a talar dome lesion is staged and what the scan findings mean

Receiving a scan report that references 'Hepple grade IV' or a '12 mm osteochondral defect' can feel more alarming than informative. Those numbers and grades are not verdicts — they are a shared language between imaging and surgical planning, and understanding what they are measuring makes the specialist conversation far easier.

Why MRI rather than X-ray?

A plain X-ray can reveal bony lesions and is still used to categorise them under the Berndt–Harty classification. Its limitation is that cartilage is invisible on X-ray: a purely chondral injury, or one with intact bone but significant cartilage loss, will simply not appear. MRI fills that gap. It shows the cartilage layer directly, maps any subchondral bone involvement, identifies fluid beneath a detached fragment, and measures whether a cyst has formed in the bone below — all of which affect what happens next.

What the Hepple grade is actually telling you

Hepple staging classifies how deeply the injury penetrates from the cartilage surface down into the bone. Lower grades indicate cartilage damage with the bone relatively preserved; higher grades — particularly grade IV and V — signal that the subchondral bone itself is affected or that a loose fragment has formed. The significance is practical: the deeper the bone involvement, the less likely conservative measures are to produce reliable healing.

Beyond the grade, lesion size — typically expressed as a diameter or area in mm² — is the single most important variable for choosing a repair technique if surgery becomes necessary. The grade tells the clinician how deep; the size tells them how wide. Together they shape the options, not close them off.

An MRI finding should always be interpreted alongside your symptoms, your level of function, and your goals. Incidental cartilage changes are not uncommon, and a good staging conversation with a specialist is what turns an imaging report into an actionable plan.

When conservative care is the right first step

Most people who attend a specialist with a confirmed talar dome lesion arrive expecting to be told they need surgery. In straightforward acute cases, that is not where the conversation starts.

For acute, undisplaced lesions — where the cartilage fragment has not shifted and there is no mechanical catching or locking — non-operative management is the appropriate first approach. Published evidence puts the success rate at roughly 50% for this group, which means it is a genuine treatment pathway, not a delay tactic. The key phrase is 'appropriate first approach': it applies to the right lesion in the right clinical setting, not to every scan finding.

The programme itself is more structured than the word 'conservative' often implies. Protected weight-bearing in a walking boot reduces load across the damaged talar surface while the subchondral bone stabilises. Anti-inflammatory medication manages pain and swelling during that period. Physiotherapy then takes over — and this is not passive rest extended by another name. The focus is on restoring ankle stability and proprioception (the joint's positional awareness, which is often disrupted after trauma), progressive load management, and neuromuscular control. Without this component, the mechanical environment around the healing lesion remains suboptimal.

A realistic trial runs to three to six months. If symptoms have not meaningfully improved within that window, the appropriate step is a structured review with a specialist — not a longer wait doing the same thing. Prolonged non-operative management beyond that point, in the absence of progress, tends to delay rather than avoid surgery.

Larger defects, displaced or unstable fragments, and lesions with significant subchondral bone involvement are considerably less likely to settle without intervention. For those presentations, specialist assessment tends to happen earlier in the pathway rather than at the end of a conservative trial.

Cartilage repair options and how lesion size shapes the choice

Three broad size thresholds guide surgical planning: small (under roughly 150 mm² on MRI), medium (around 1–2 cm²), and large (beyond 3–4 cm²). Clinical context — lesion location, bone involvement, prior treatment — always shapes the final choice within those bands.

Small lesions: microfracture as the starting point

For smaller lesions, arthroscopic bone marrow stimulation (microfracture) is the established first-line surgical approach. The technique perforates subchondral bone to release marrow cells that form repair tissue at the surface. In a retrospective series of 105 ankle cartilage lesions, no treatment failures were recorded for defects averaging below 15 mm in diameter. Two factors further strengthen the prognosis: age under 40 years, and a lateral rather than medial lesion location. A 2025 systematic review and meta-analysis of 257 patients found that small accompanying subchondral cysts — depth under 5–6 mm — did not significantly alter microfracture outcomes in younger patients, which is a useful reassurance for those whose scan shows early cyst formation.

Scaffold augmentation: targeting better-quality repair tissue

Microfracture tends to produce fibrocartilage rather than the hyaline cartilage it replaces — functional, but potentially less durable over time. Scaffold-augmented approaches overlay a biological matrix on the microfracture bed to encourage more hyaline-like repair. Injectable collagen scaffold, delivered as an outpatient ultrasound-guided procedure, is one route within this category. Trial data comparing atelocollagen-augmented chondrogenesis with microfracture alone found superior patient satisfaction and quality-of-life domain scores at one year, with comparable objective clinical scores between groups.

Medium-to-large and recurrent lesions

Beyond approximately 1.5 cm², or where an earlier procedure has not held, two further biological options arise. Autologous bone grafting with a periosteal patch — performed as a single stage — has produced marked functional gains in published series: one 30-patient prospective study recorded AOFAS scores rising from 40.6 to 95.1 and VAS pain scores falling from 7.1 to 0.4 at final follow-up. OATS (osteochondral autograft transfer) is a further option for active patients, replacing damaged cartilage and underlying bone with the patient's own living osteochondral tissue. Long-term comparative data between these techniques for mid-size lesions remain limited, and a specialist review is needed to weigh the options carefully.

The largest defects

Defects exceeding 3–4 cm², or those with deep bone penetration beyond the reach of standard repair, move into allograft territory. Osteochondral allograft transplantation replaces both cartilage and bone from a donor in a single operation — a biological salvage step positioned before ankle fusion or joint replacement becomes the conversation.

A note for patients who smoke

Smokers achieve similar functional scores to non-smokers after microfracture at long-term follow-up, but MRI assessment of the repair tissue shows meaningfully lower quality — particularly for surface integrity and signal characteristics. That distinction between functional scores and tissue quality is worth raising with a specialist before settling on a treatment plan.

Recovery, return to activity, and next steps

Recovery after a talar dome repair is determined by what the joint has been through, not by a fixed countdown. Microfracture relies on marrow-derived cells consolidating at the treated surface — a process that calls for protected weight-bearing before load is progressively restored. Graft-based procedures carry an additional bone integration phase. Injectable collagen scaffold approaches have their own maturation arc, governed by matrix remodelling rather than bone healing alone.

Across all techniques, return to activity is assessed rather than scheduled. The relevant markers are functional ones: restored ankle stability, symmetry on single-leg load testing, proprioceptive accuracy, and tolerance of graded impact without reactive swelling. A supervised return-to-running protocol precedes any return to sport, and impact load is reintroduced in stages rather than all at once. Ankle stability and proprioception work form the core of any structured rehabilitation programme — neuromuscular control determines whether load on the repair site is protective or damaging, and that cannot be shortcut by time alone.

For anyone with persistent deep ankle pain where conservative management has not brought meaningful improvement, a specialist assessment with dedicated MRI review is the logical next step — both to clarify what is happening structurally and to map the available options. Patients based in London can arrange that assessment at the London Cartilage Clinic on Harley Street (londoncartilage.com), where the outpatient ChondroFiller injection pathway is one of the biological options reviewed at initial consultation.

1. [1] Osteochondritis dissecans. https://en.wikipedia.org/?curid=3762029 https://en.wikipedia.org/?curid=3762029
2. [2] Factors predicting the outcome of arthroscopic debridement and microfracture technique in treatment of OLT. (2024). https://doi.org/10.1097/BCO.0000000000001259 https://doi.org/10.1097/BCO.0000000000001259
3. [3] Autologous bone graft and periosteal patch for large and recurrent talar osteochondral defect: A prospective study. (2025). https://doi.org/10.1016/j.jcot.2025.103132 https://doi.org/10.1016/j.jcot.2025.103132
4. [4] Osteochondral lesions of the talus with small cysts may not affect the outcome of arthroscopic microfracture: A systematic review and meta-analysis. (2025). https://doi.org/10.1016/j.fas.2025.01.004 https://doi.org/10.1016/j.fas.2025.01.004